AVTX (Avalo Therapeutics) OCF Yield %: -6.24 (As of Jun. 26, 2026)


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $18.20
GF Value $0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics OCF Yield %?

Avalo Therapeutics AVTX +1.11% 23 OCF Yield % is -6.24 as of Jun. 26, 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,419 Biotechnology companies, Avalo Therapeutics ranks better than 55.39% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Avalo Therapeutics's Trailing 12-Month Cash Flow from Operations is $-59.69 Mil, and Market Cap is $956.69 Mil. Therefore, Avalo Therapeutics's OCF Yield % for today is -6.24%.

The historical rank and industry rank for Avalo Therapeutics's OCF Yield % or its related term are showing as below:

AVTX' s OCF Yield % Range Over the Past 10 Years
Min: -1795.1   Med: -31.32   Max: 35.9
Current: -6.24


During the past 13 years, the highest OCF Yield % of Avalo Therapeutics was 35.90%. The lowest was -1795.10%. And the median was -31.32%.

AVTX's OCF Yield % is ranked better than
55.39% of 1419 companies
in the Biotechnology industry
Industry Median: -8.48 vs AVTX: -6.24

Avalo Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Avalo Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Avalo Therapeutics OCF Yield % Related Terms


Avalo Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics OCF Yield % Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -37.13 -56.71 -420.38 -63.05 -15.31

Avalo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.61 -84.25 -28.89 -16.95 -19.24

AVTX vs EVMN, TBPH, VOR: OCF Yield % Comparison

For the Biotechnology subindustry, Avalo Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's OCF Yield % falls into.


AVTX
23GF Score
Avalo Therapeutics Inc AVTX
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Avalo Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-51.458 / 336.19608
=-15.31%

Avalo Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-17.691 * 4 / 367.84534
=-19.24%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -6.24 mean?
Avalo Therapeutics (AVTX) has a OCF Yield % of -6.24 as of Jun. 26, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Avalo Therapeutics and its competitors. According to the industry distribution chart, Avalo Therapeutics ranks #633 out of 1419 companies in the Biotechnology industry, placing it in the top 44.6%.
Is Avalo Therapeutics' OCF Yield % too high?
Avalo Therapeutics' current OCF Yield % is -6.24. Based on the distribution chart, Avalo Therapeutics ranks #633 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' OCF Yield % compare to EVMN and TBPH?
According to the Biotechnology industry distribution chart, Avalo Therapeutics ranks #633 out of 1419 companies for OCF Yield %. This puts Avalo Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Avalo Therapeutics and its competitors. Avalo Therapeutics's current OCF Yield % is -6.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $18.20 — trading 60566.7% above its estimated fair value. The current OCF Yield % is -6.24. Avalo Therapeutics' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current OCF Yield % is -6.24 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $18.20 is trading 60566.7% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • OCF Yield %: -6.24
  • GF Value™: $0.03 vs. price of $18.20 (60566.7% above fair value)
  • GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.20
Price
$0.03
GF Value